Pfizer raises its outlook, but COVID sales still drag

A guidance raise without a broad sales rebound

Pfizer raised its full-year outlook on November 3, 2026, but the quarter tells a two-speed story. Third-quarter revenue was US$16.583 billion versus US$16.654 billion a year earlier, a US$71 million decline, or a calculated 0.43%. Reported diluted earnings were US$0.56 per share, down from US$0.62; adjusted diluted earnings held at US$0.87. Adjusted and reported profit are different measures, not interchangeable versions of the same result. 1

The share reaction was restrained. Yahoo’s November 3 snapshot at 14:07:20 ET showed PFE at US$30.435, down US$0.235, or 0.77%, from the November 2 close of US$30.67. Cumulative volume was 26,400,344 shares versus a preceding 20-session average of 30,691,645. That 0.86-times comparison uses full-day historical volumes: it is not adjusted for the unfinished session or a forecast of the close. 2

What is doing the work beneath the headline

Excluding Comirnaty and Paxlovid, quarterly revenue grew 7% operationally, meaning Pfizer’s comparison excludes currency movements. Launched and acquired products grew 32% on that basis. Those figures describe selected business groupings, not 7% or 32% growth in total company revenue. The distinction matters when evaluating whether newer medicines can replace fading pandemic-era demand. 1

• Eliquis added US$513 million of operational revenue, up 25%, helped by U.S. pricing dynamics, channel mix and global demand. That is not purely prescription-volume growth. 1
• Padcev added US$255 million, up 55% operationally, with market-share gains and launch uptake supporting the oncology business. 1
• Paxlovid fell US$771 million, or 63%, operationally; Comirnaty fell US$339 million, or 29%. These declines explain much of the gap between non-COVID momentum and flat overall sales. 1

Management lifted the revenue-guidance midpoint from US$61.5 billion to US$63.0 billion. The adjusted-EPS midpoint rose from US$2.90 to US$3.00, a calculated 3.45% increase. The outlook includes a US$650 million acquired in-process research charge tied to Innovent, with an approximately US$0.10 unfavorable EPS impact. Guidance is management’s forecast, not profit already earned. 1

Sector context is a cross-check, not a cause

Merck’s October 29 results offer a useful pharmaceutical comparison: Q3 sales were US$18.085 billion, up 5% as reported and 4% excluding foreign exchange. Pfizer’s roughly flat total revenue therefore should not be mistaken for a sector-wide growth rate. Product portfolios and comparison bases differ, so a peer’s growth is context rather than a promise for Pfizer. 3

At Yahoo’s November 3 snapshots around 14:07 ET, MRK was down a calculated 2.57% while SPY was up 0.50%, each versus its prior close. That split argues against explaining Pfizer’s decline solely as a broad-market selloff. It does not prove which specific investor concern set PFE’s price. 4 5

The dated macro backdrop also matters. On October 28, the Federal Reserve maintained its policy target at 3.75–4.00% and said inflation remained elevated. Interest-rate expectations can affect how investors compare equities and cash, but that policy statement does not establish the cause of Pfizer’s intraday move. 8

What it means for option sellers

Cboe’s 15-minute-delayed file retrieved November 3 at 14:07 ET showed 30-day implied volatility of 26.277%, rounded to 26.28%. Its latest underlying trade was stamped 13:51:18 ET. IV rank was not verified, so there is no basis here to call premiums historically rich or cheap. This is a frozen snapshot; check live prices before trading. 6

• For the wheel, assignment converts a short-put obligation into stock exposure; writing calls afterward does not undo a price decline. 10
• Compare actual contract spreads and liquidity separately. A company-level IV reading does not establish whether a particular strike is practical to trade.
• The Q3 release is already out, but a future earnings date was not independently established here. November 20 is not certified earnings-free; pipeline and regulatory headlines can also change the risk. 1

What to watch next

• November 5–6: the approach to the November 6 ex-dividend date is the immediate covered-call assignment checkpoint. Payment follows December 7. 7 11
• November 20: the illustrative put expires; its assumed premium is not a live trading opportunity. Check actual contract terms and the intervening calendar.
• December 8–9: the next scheduled FOMC meeting provides a dated macro checkpoint, with the decision on December 9. 9

The next business test is whether Eliquis and newer medicines can keep offsetting weaker COVID products without confusing adjusted earnings with reported earnings. The guidance raise improves management’s outlook; it does not eliminate sales, research or stock-price risk. For option sellers, the dividend calendar and willingness to own the shares matter more than a headline yield.